PML A216V

CI-VAR-00000083Explore in graph →CIViC 462

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Promyelocytic Leukemia2
PML::RARA Fusion AND PML A216V	Arsenic Trioxide	Predictive	B	Supports Resistance	4	accepted	EID8177 Five point mutations were identified in the PML B2 domain of PML-RARA transcripts in 9 patients diagnosed with APL and resistant to arsenic. DNA from these 9 patients was cloned into flag-tagged pCag … (full text at CIViC) PMID 26537301 · Liu et al., 2016 · Open in CIViC	civic
PML::RARA Fusion AND PML A216V	Tretinoin	Predictive	C	Supports Resistance	4	accepted	EID1093 The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia. PMID 21613260 · Goto et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.